Business Description
Faeth Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US81728A2078
Share Class Description:
FTH: Ordinary SharesTotal Employee Number:
29Description
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 194.99 | |||||
Equity-to-Asset | -0.67 | |||||
Debt-to-Equity | -0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 18.5 | |||||
3-Year EPS without NRI Growth Rate | 19.1 | |||||
3-Year FCF Growth Rate | 14.1 | |||||
3-Year Book Growth Rate | -39.7 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 89.53 | |||||
9-Day RSI | 75.64 | |||||
14-Day RSI | 65.41 | |||||
3-1 Month Momentum % | -45.73 | |||||
6-1 Month Momentum % | 93.16 | |||||
12-1 Month Momentum % | 120.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 14.39 | |||||
Quick Ratio | 14.39 | |||||
Cash Ratio | 14.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 6.4 | |||||
Shareholder Yield % | 0.38 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -282.97 | |||||
ROIC % | -3541.15 | |||||
3-Year ROIIC % | -275.23 | |||||
ROC (Joel Greenblatt) % | -10384.87 | |||||
ROCE % | -314.39 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -2.33 | |||||
EV-to-Forward-EBIT | -0.53 | |||||
EV-to-EBITDA | -2.33 | |||||
EV-to-Forward-EBITDA | -2.1 | |||||
EV-to-FCF | -17.88 | |||||
Earnings Yield (Greenblatt) % | -42.92 | |||||
FCF Yield % | -3.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FTH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Faeth Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -142.72 | ||
| Beta | -0.842 | ||
| 3-Year Sharpe Ratio | 0.25 | ||
| 3-Year Sortino Ratio | 0.85 | ||
| Volatility % | 228.88 | ||
| 14-Day RSI | 65.41 | ||
| 14-Day ATR ($) | 3.196719 | ||
| 20-Day SMA ($) | 16.3035 | ||
| 12-1 Month Momentum % | 120.72 | ||
| 52-Week Range ($) | 6.325 - 36.76 | ||
| Shares Outstanding (Mil) | 25.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Faeth Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Faeth Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 142 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 42 days | ||
| General meeting for 2026 | 2026-06-10 11:00 | 12.63 (-1.41%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 19.82 (-4.07%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-16 12:45 | 29.21 (-0.31%) | ||
| Annual report for 2025 | 2026-03-30 | 27.68 (+2.71%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 27.68 (+2.71%) | ||
| Sensei Acquisition of Faeth Therapeutics | 2026-02-18 08:30 | 9.13 (+0.22%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 9.02 (-7.01%) | ||
| Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors | 2025-10-20 08:00 | 11.70 (-22.26%) |
Show
Entries
Faeth Therapeutics Inc Frequently Asked Questions
What is Faeth Therapeutics Inc(FTH)'s stock price today?
The current price of FTH is $24.54. The 52 week high of FTH is $36.76 and 52 week low is $6.33.
When is next earnings date of Faeth Therapeutics Inc(FTH)?
The next earnings date of Faeth Therapeutics Inc(FTH) is 2026-08-05 Est..
Does Faeth Therapeutics Inc(FTH) pay dividends? If so, how much?
Faeth Therapeutics Inc(FTH) does not pay dividend.
Guru Commentaries on NAS:FTH
No articles.
Press Release
Articles on Faeth Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers